Breaking News Instant updates and real-time market news.

PFE

Pfizer

$32.67

-0.28 (-0.85%)

, BMY

Bristol-Myers

$56.42

-0.35 (-0.62%)

16:05
08/19/17
08/19
16:05
08/19/17
16:05

Pharmaceutical companies not the only ones with healthy dividends, Barron's says

Most income investors are drawn to pharmaceutical stocks, because many offer attractive yields, such as Pfizer (PFE) or Bristol Myers (BMY), Lawrence Strauss writes in this week's edition of Barron's. However, the publication says it has found healthy dividends in neighboring companies that have yields of at least 1.5% and payout ratios of less than 50%, namely Cardinal Health (CAH), Patterson Companies (PDCO), ResMed (RMD), AmerisourceBergen (ABC), and AmerisourceBergen (UNH). Reference Link

PFE

Pfizer

$32.67

-0.28 (-0.85%)

BMY

Bristol-Myers

$56.42

-0.35 (-0.62%)

CAH

Cardinal Health

$64.38

-0.78 (-1.20%)

PDCO

Patterson Companies

$36.45

-0.31 (-0.84%)

RMD

ResMed

$73.07

0.28 (0.38%)

ABC

AmerisourceBergen

$78.60

-1.34 (-1.68%)

UNH

UnitedHealth

$190.82

-1.88 (-0.98%)

  • 24

    Aug

  • 27

    Aug

  • 28

    Aug

  • 06

    Sep

  • 08

    Sep

  • 08

    Sep

  • 11

    Sep

  • 11

    Sep

  • 13

    Sep

  • 18

    Sep

  • 21

    Sep

  • 22

    Sep

  • 24

    Sep

  • 09

    Nov

  • 05

    Mar

PFE Pfizer
$32.67

-0.28 (-0.85%)

08/16/17
FBCO
08/16/17
NO CHANGE
Target $58
FBCO
Neutral
Reaction to Bristol-Myers CM-214 data 'overly pessimistic,' says Credit Suisse
Credit Suisse analyst Vamil Divan notes that Bristol-Myers (BMY) reported topline data for the Phase 3 CheckMate-214 study of Opdivo + Yervoy in 1st line renal cell carcinoma. For the first two co-primary endpoints in the trial, the results were mixed, with the combination showing an improved objective response rate as compared to Pfizer's (PFE) Sutent but narrowly missing statistical significance on improved progression-free survival, he adds. With the revenue opportunity being pushed out and potentially down due to added competition, the analyst feels modest weakness in Bristol-Myers shares is reasonable, although the actual decline seen seems "a little excessive." Divan reiterates a Neutral rating and $58 price target on Bristol-Myers shares.
08/02/17
08/02/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Pfizer (PFE) upgraded to Outperform from Market Perform at BMO Capital with analyst Alex Arfaei saying he expects "positive updates" on the company's pipeline that could improve investors' view on the company. 2. Royal Caribbean (RCL) upgraded to Neutral from Sell at Goldman Sachs with analyst Stephen Grambling citing "strong" leisure trends following the company's better than expected second quarter results. 3. Illumina (ILMN) upgraded to Equal-Weight from Underweight at First Analysis with analyst Joseph Munda saying concerns regarding sequencing overcapacity in the marketplace and the potential rate of adoption for NovaSeq are diminishing based on performance in the quarter. 4. Agios Pharmaceuticals (AGIO) upgraded to Outperform from Market Perform at Leerink with analyst Michael Schmidt citing his higher-level conviction regarding the commercial opportunity for its IDH inhibitors Idhifa and ivosidenib in acute myeloid leukemia following Idhifa FDA-approval and his recent checks indicating a high degree of enthusiasm for these agents in the physician community pointing to potential good initial uptake. 5. Sonoco Products (SON) upgraded to Hold from Sell at Vertical Research with analyst Chip Dillion citing valuation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/02/17
BMOC
08/02/17
UPGRADE
BMOC
Outperform
Pfizer upgraded on growth outlook, pipeline, risk/reward at BMO Capital
As noted earlier, BMO Capital upgraded Pfizer to Outperform from Market Perform. Analyst Alex Arfaei says he expects "positive updates" on the company's pipeline that could improve investors' view on the company. He thinks that its revenue is poised to increase about 2%-3% annually, while its EPS should rise by single percentage digits. The analyst says that the stock poses little risk "given low pipeline expectations, a dividend yield of about 4%, and significant share buybacks." Target to $37 from $33.
08/02/17
BMOC
08/02/17
UPGRADE
BMOC
Outperform
Pfizer upgraded to Outperform from Market Perform at BMO Capital
BMY Bristol-Myers
$56.42

-0.35 (-0.62%)

08/08/17
GSCO
08/08/17
NO CHANGE
GSCO
Bristol-Myers stock could be worth $64-$74 per share, says Goldman Sachs
Goldman Sachs analyst Jami Rubin believes that Bristol-Myers could be worth $64-$74 per share ,depending on the outcome of a trial of its CM-227 cancer treatment. The analyst notes that if the trial is successful, the company will have the only IO treatment that works in conjunction with the CTLA-4 protein receptor, and Rubin says this will be "particularly meaningful"if patients taking CM-227 show.a higher overall survival rate than those taking chom combos. Rubin thinks the stock could be worth $59-$75 per share in a takeover with no value for CM-227, and the analyst says that at $50 per share the stock is reflecting no value for the company's first line NSCLC treatment. Rubin keeps the stock on the Americas Buy List.
08/16/17
LEER
08/16/17
NO CHANGE
Target $34
LEER
Outperform
Leerink sees competitor setback in RCC opportunity for Exelixis
Leerink analyst Michael Schmidt notes that Bristol-Myers (BMY) reported top-line results from the Phase III CheckMate-214 trial investigating Opdivo in combination with Yervoy versus Sutent in intermediate and poor-risk patients with previously untreated advanced or metastatic renal cell carcinoma, or RCC. While directionally positive, the trial missed the co-primary endpoint of improving progression-free survival with statistical significance, he notes, adding that this raises the regulatory bar for Bristol-Myers' IO combination at least until positive overall survival data are available likely in mid-2019, which he thinks will be positively received by Exelixis (EXEL) investors. Following the news, Schmidt believes Exelixis continues to look well positioned in RCC, He reiterates an Outperform rating and $34 price target on the latter's shares.
08/16/17
PIPR
08/16/17
NO CHANGE
Target $29
PIPR
Overweight
After Bristol data, Piper continues to expect approval for Exelixis
Bristol-Myers Squibb (BMY) reported "mixed" top-line Phase III CheckMate-214 data on 1,070 front-line metastatic renal cell carcinoma patients, Piper Jaffray analyst Edward Tenthoff tells investors in a research note. He continues to expect a front-line renal cell carcinoma supplemental new drug application for Exelixis' (EXEL) Cabometyx in Q3 with approval next year. Tenthoff anticipates Cabometyx use in front-line RCC expanding the current market opportunity before ultimately showing IO combination benefit. The analyst reiterates an Overweight rating on Exelixis shares with a $29 price target.
CAH Cardinal Health
$64.38

-0.78 (-1.20%)

07/13/17
FBCO
07/13/17
NO CHANGE
Target $87
FBCO
Outperform
Cardinal Health price target raised to $87 from $81 at Credit Suisse
Credit Suisse analyst Erin Wilson Wright raised her price target for Cardinal Health to $87 from $81 given the company's recent acquisition of Medtronic's patient recovery business. The analyst reiterates an Outperform rating on the shares.
08/09/17
BARD
08/09/17
NO CHANGE
BARD
Neutral
AmerisourceBergen settlement ups odds of PharMerica switch, says Baird
Baird analyst Eric Coldwell said AmerisourceBergen's (ABC) 10-Q last week showed that the company and PharMerica (PMC) have tentatively agreed to settle their long-running legal fight, which he reads as significantly increasing the odds of AmerisourceBergen displacing incumbent Cardinal Health (CAH) after KKR (KKR) and minority investor Walgreens (WBA) complete their deal to buy PharMerica. Coldwell has a Neutral rating and $89 price target on AmerisourceBergen shares.
08/03/17
FBCO
08/03/17
NO CHANGE
Target $81
FBCO
Outperform
Cardinal Health price target lowered to $81 from $87 at Credit Suisse
Credit Suisse analyst Erin Wilson Wright lowered her price target for Cardinal Health to $81 from $87, citing on a "surprising" cut to 2018 EPS guidance primarily on incremental investment initiatives across its businesses, further defining 2018 as a transition year. The analyst reiterates an Outperform rating on the shares.
07/03/17
BARD
07/03/17
NO CHANGE
Target $75
BARD
Neutral
Cardinal Health confirms deal to buy Liberty Medical, says Baird
Baird analyst Eric Coldwell said that Cardinal Health has confirmed a deal to buy Liberty Medical, a direct-to-patient provider of diabetes supplies and products that is well known for its commercials featuring actor Wilford Brimley. The small deal, which is immaterial to his model, enhances Cardinal's direct-to-patient platform primarily in diabetes and likely also adds volume in ostomy and urology, Coldwell tells investors. He keeps a Neutral rating and $75 price target on Cardinal Health shares.
PDCO Patterson Companies
$36.45

-0.31 (-0.84%)

07/26/17
GSCO
07/26/17
NO CHANGE
GSCO
Dental survey indicates Q2 upside for Align, Henry Schein, says Goldman Sachs
Goldman analyst Robert Jones said checks indicate Q2 Dental trends remained stable and point to consistent low-single-digit growth end-markets. The analyst likes Align Technology (ALGN) saying Q2 case guidance appears beatable and expects high 20% case growth driven by investments, sees Q2 upside for Henry Schein (HSIC) due to share gains from Patterson Companies (PDCO), and said Dentsply Sirona (XRAY) promotions to drive cross-selling have yet to gain traction and 2017 guidance may be aggressive, but expectations are low into the quarter.
08/17/17
CHLM
08/17/17
NO CHANGE
Target $41
CHLM
Hold
Patterson Companies price target lowered to $41 from $46 at Craig-Hallum
Craig-Hallum analyst Kevin Ellich lowered his price target for Patterson Companies(PDCO) to $41 from $46 to reflect the soft dental consumable environment and potential market share losses once Henry Schein (HSIC) starts to sell CEREC on September 1. Given the lower valuation and good, stable end markets, the analyst thinks Patterson Companies could be an "interesting target" for a financial buyer as cash flow should start to improve over the next few quarters once the company completes the ERP implementation. He reiterates a Hold rating on Patterson Companies' shares.
08/01/17
NRCS
08/01/17
NO CHANGE
Target $76
NRCS
Buy
Dentsply Sirona estimaters reduced at Northcoast
Northcoast analyst Ed Snyder's checks indicate Patterson Companies (PDCO) sales of high technology dental equipment is weaker than expected caused by industry competition. Snyder said it appears Patterson's CEREC sales growth is down about 40-50%, despite promotional activity. As a result, he reduced Dentsply Sirona's (XRAY) second half internal growth estimate to 1.4% from 2.3% and earnings FY17 earnings estimate to $2.80 from $2.82. Snyder retains a Buy rating on Dentsply and a $76 price target.
07/13/17
FBCO
07/13/17
NO CHANGE
Target $50
FBCO
Outperform
Patterson Companies price target raised to $50 from $45 at Credit Suisse
Credit Suisse analyst Erin Wilson Wright raised her price target for Patterson Companies to $50 from $45 to be more in line with industry peers. The analyst reiterates an Outperform rating on the shares.
RMD ResMed
$73.07

0.28 (0.38%)

08/02/17
BOFA
08/02/17
DOWNGRADE
BOFA
Neutral
ResMed downgraded to Neutral from Buy at BofA/Merrill
BofA/Merrill analyst William Dunlop downgraded ResMed to Neutral with a reduced price target of A$9.90. The analyst says the company's FY18 gross margin range of around 58.2% lessen his enthusiasm for its CPAP business prospects.
08/02/17
SBSH
08/02/17
UPGRADE
SBSH
Buy
ResMed upgraded to Buy from Neutral at Citi
Citi analyst Victor Windeyer upgraded ResMed to Buy with following the company's Q4 results. Credit Suisse and BofA/Merrill downgraded the shares this morning. The analyst believes supply bottlenecks have been removed and that the mask category can return to growth. He raised his price target for ResMed shares to A$10.50 from A$10.
08/02/17
08/02/17
DOWNGRADE

Neutral
ResMed downgraded to Neutral at Credit Suisse
As previously reported, Credit Suisse analyst Saul Hadassin downgraded ResMed to Neutral from Outperform following the company's Q4 in line earnings. The analyst also lowered his price target on the shares to A$9.40 from A$9.70.
08/02/17
08/02/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Under Armour (UA, UAA) downgraded to Neutral from Buy at Citi with analyst Kate McShane citing yesterday's guide-down, the shares look "too expensive for investors to jump into the name nearer-term." 2. Burlington Stores (BURL) downgraded to Neutral from Outperform at Credit Suisse with analyst Christian Buss saying that although the fundamentals of the company remain healthy, he sees limited upside to valuation as the multiples stay elevated despite more moderate industry growth prospects. 3. Big 5 Sporting (BGFV) downgraded to Hold from Buy at Deutsche Bank with analyst Mike Baker saying he expected Big Five's sales gains following The Sports Authority liquidation would decelerate at some point, but he notes that "trends fell off faster and to a greater extent than we suspected." 4. Ultimate Software (ULTI) downgraded to Hold from Buy at Deutsche Bank with analyst Nandan Amladi calling the second quarter results "mixed" and prefers to move to the sidelines until growth returns to the mid-20s target and leverage returns to the model. 5. ResMed (RMD) was downgraded to Neutral from Buy at BofA/Merrill and to Neutral from Outperform at Credit Suisse. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
ABC AmerisourceBergen
$78.60

-1.34 (-1.68%)

08/07/17
LEER
08/07/17
NO CHANGE
Target $90
LEER
Outperform
AmerisourceBergen price target lowered to $90 from $100 at Leerink
Leerink analyst David Larsen lowered his price target for AmerisourceBergen to $90 from $100 noting that while its Q3 earnings results were largely in-line with consensus and guidance, the stock has sold off due to a lack of clarity around guidance for 2018. Nonetheless, the analyst reiterates an Outperform rating on the shares.
08/02/17
LEER
08/02/17
NO CHANGE
LEER
AmerisourceBergen may benefit from PharMerica takeover, says Leerink
Leerink analyst David Larsen believes AmerisourceBergen (ABC) could benefit from KKR's (KKR) buyout of PharMerica (PMC). KKR and Walgreens Boots Alliance (WBA), which uses AmerisourceBergen as a supplier, are forming a new private company which would hold PharMerica, Larsen tells investors in a research note. He believes PharMerica may switch away from its current supplier Cardinal Health (CAH) as a result of today's deal and use AmerisourceBergen. Any potential change in distributor contracts would likely occur in the second half of 2018, the analyst adds.
07/13/17
FBCO
07/13/17
NO CHANGE
Target $105
FBCO
Outperform
AmerisourceBergen price target raised to $105 from $95 at Credit Suisse
Credit Suisse analyst Erin Wilson Wright raised her price target for AmerisourceBergen to $105 from $95 to be more in line with the distributor group average. The analyst reiterates an Outperform rating on the shares.
UNH UnitedHealth
$190.82

-1.88 (-0.98%)

07/19/17
UBSW
07/19/17
NO CHANGE
Target $213
UBSW
Buy
UnitedHealth price target raised to $213 from $194 at UBS
UBS analyst A.J. Rice raised his price target on UnitedHealth to $213 from $194 following Q2 earnings. The analyst cited the company's positive outlook to gain market share in both group and individual Medicare Advantage markets along with continued growth assumptions for Optum Rx. Rice reiterated his Buy rating on UnitedHealth shares.
07/28/17
WELS
07/28/17
NO CHANGE
Target $9
WELS
Underperform
Insurers are dropping Valeant's top products, says Wells Fargo
United Healthcare's (UNH) formulary is no longer covering Valeant Pharmaceuticals' (VRX) number three branded drug Solodyn and will also now exclude Retin-A brand, its number four branded drug, Wells Fargo analyst David Maris tells investors in a research note. The analyst estimates the two drugs represented approximately $214M of Valeant's sales in 2016. Maris also points out that Glumetza, Valeant's number eight branded drug, and Relistor were removed in July from CVS/Caremark's (CVS) formulary. These two drugs had approximately $119M in 2016 revenues. Maris notes his counterpart Peter Costa estimates that United Healthcare covers approximately 17% of the U.S. and CVS covers approximately 33%. Express Scripts (ESRX) is releasing its 2018 national formulary next week, Costa adds. Maris keeps an Underperform rating on shares of Valeant with a $9 price target. The stock in premarket trading is down 33c, or 2%, to $16.80.
08/11/17
COWN
08/11/17
NO CHANGE
Target $220
COWN
Outperform
UnitedHealth price target raised to $220 from $175 at Cowen
Cowen analyst Christine Arnold raised her price target on UnitedHealth to $220 from $175. The analyst believes the company can achieve its long-term growth targets in 2018, citing Medicare Advantage enrollment growth, operating efficiencies, commercial market penetration, and OptumRx and OptumInsight earnings gains. Arnold reiterated her Outperform rating on UnitedHealth shares.
08/16/17
PIPR
08/16/17
NO CHANGE
PIPR
Overweight
UnitedHealth made 'solid choice' in new CEO, says Piper Jaffray
Piper Jaffray analyst Sarah James views UnitedHealth's promotion of David Wichmann as a "solid choice and not a surprise." The analyst expects business as usual for the company as it continues to push into technology including artificial intelligence. She has an Overweight rating on the shares.

TODAY'S FREE FLY STORIES

CELC

Celcuity

20:34
09/19/17
09/19
20:34
09/19/17
20:34
Syndicate
Celcuity 2.4M share IPO priced at $9.50 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 20

    Sep

BSTI

BEST Inc

20:33
09/19/17
09/19
20:33
09/19/17
20:33
Syndicate
Best Inc 45M share IPO priced at $10.00 »

The deal priced at the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

GIS

General Mills

$55.38

-1.05 (-1.86%)

20:25
09/19/17
09/19
20:25
09/19/17
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

PCRX

Pacira

$35.70

-0.6 (-1.65%)

20:00
09/19/17
09/19
20:00
09/19/17
20:00
Recommendations
Pacira analyst commentary at BMO Capital »

Pacira's Exparel…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

AVEVF

Aveva

19:56
09/19/17
09/19
19:56
09/19/17
19:56
Upgrade
Aveva rating change at Goldman Sachs »

Aveva upgraded to Neutral…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZLAB

Zai Lab

18:58
09/19/17
09/19
18:58
09/19/17
18:58
Syndicate
Zai Lab announces upsizing of U.S. IPO of American depositary shares »

Zai Lab announces its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

OHI

Omega Healthcare

$32.53

-0.12 (-0.37%)

18:30
09/19/17
09/19
18:30
09/19/17
18:30
Hot Stocks
Omega Healthcare provides hurricane update »

Omega Healthcare provided…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

F

Ford

$11.72

0.09 (0.77%)

18:30
09/19/17
09/19
18:30
09/19/17
18:30
Periodicals
Ford to slash production at five North American assembly plants, Reuters says »

Ford announced it intends…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 03

    Oct

  • 26

    Oct

FDX

FedEx

$216.00

0.92 (0.43%)

18:26
09/19/17
09/19
18:26
09/19/17
18:26
Hot Stocks
FedEx says without cyberattack FY18 guidance would not have changed »

Comments are from the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 21

    Sep

  • 25

    Sep

EE

El Paso Electric

$54.85

0.05 (0.09%)

18:25
09/19/17
09/19
18:25
09/19/17
18:25
Hot Stocks
El Paso Electric announces City of El Paso approved settlement terms »

El Paso Electric…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BBBY

Bed Bath & Beyond

$27.03

-0.27 (-0.99%)

18:17
09/19/17
09/19
18:17
09/19/17
18:17
Hot Stocks
Bed Bath & Beyond says biggest component in drop of FY17 EPS view is operations »

Company dropped its FY17…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

CPRT

Copart

$32.54

-0.32 (-0.97%)

18:11
09/19/17
09/19
18:11
09/19/17
18:11
Earnings
Copart reports Q4 EPS 30c, consensus 29c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

STLD

Steel Dynamics

$33.83

0.03 (0.09%)

18:04
09/19/17
09/19
18:04
09/19/17
18:04
Earnings
Steel Dynamics sees Q3 adjusted EPS 63c-67c, consensus 70c »

Steel Dynamics provided…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XBKS

Xenith Bankshares

$29.96

0.42 (1.42%)

17:58
09/19/17
09/19
17:58
09/19/17
17:58
Hot Stocks
Treasury exits stake in Xenith Bankshares »

Xenith Bankshares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BMY

Bristol-Myers

$62.93

0.23 (0.37%)

17:54
09/19/17
09/19
17:54
09/19/17
17:54
Periodicals
Breaking Periodicals news story on Bristol-Myers »

Times:NHS will supply…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 25

    Sep

  • 26

    Sep

  • 18

    Oct

  • 26

    Oct

  • 09

    Nov

  • 05

    Mar

BBBY

Bed Bath & Beyond

17:54
09/19/17
09/19
17:54
09/19/17
17:54
Hot Stocks
Breaking Hot Stocks news story on Bed Bath & Beyond »

Bed Bath & Beyond…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

DESP

Despegar.com

17:52
09/19/17
09/19
17:52
09/19/17
17:52
Syndicate
Despegar.com 12.7M share IPO priced at $26.00 »

The IPO priced at the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

WAC

Walter Investment

$0.65

0.186 (40.09%)

17:50
09/19/17
09/19
17:50
09/19/17
17:50
Hot Stocks
Walter Investment says Barclays to increase financing available »

On September 13, Walter…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CBAY

CymaBay

17:49
09/19/17
09/19
17:49
09/19/17
17:49
Initiation
CymaBay initiated at Cantor »

CymaBay initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 27

    Sep

BBBY

Bed Bath & Beyond

17:46
09/19/17
09/19
17:46
09/19/17
17:46
Hot Stocks
Bed Bath & Beyond sees net drop in Bed Bath & Beyond stores in FY17 »

Says rate of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

EVH

Evolent Health

$15.65

-0.8 (-4.86%)

17:45
09/19/17
09/19
17:45
09/19/17
17:45
Initiation
Evolent Health initiated at KeyBanc »

Evolent Health initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

BPL

Buckeye Partners

$56.33

0.64 (1.15%)

17:44
09/19/17
09/19
17:44
09/19/17
17:44
Syndicate
Buckeye Partners announces $210M in limited partnership unit sales »

Buckeye Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RL

Ralph Lauren

$91.03

0.87 (0.96%)

17:43
09/19/17
09/19
17:43
09/19/17
17:43
Initiation
Ralph Lauren initiated at Barclays »

Ralph Lauren initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

  • 04

    Oct

PVH

PVH Corp.

$127.47

-0.54 (-0.42%)

17:43
09/19/17
09/19
17:43
09/19/17
17:43
Initiation
PVH Corp. initiated at Barclays »

PVH Corp. initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

GEMP

Gemphire Therapeutics

$9.65

0.54 (5.93%)

, ORIG

Ocean Rig UDW

$0.16

-0.0083 (-4.90%)

17:43
09/19/17
09/19
17:43
09/19/17
17:43
Hot Stocks
On The Fly: After Hours Movers »

HIGHER: Gemphire…

GEMP

Gemphire Therapeutics

$9.65

0.54 (5.93%)

ORIG

Ocean Rig UDW

$0.16

-0.0083 (-4.90%)

IOVA

Iovance Biotherapeutics

$8.55

0.3 (3.64%)

BBBY

Bed Bath & Beyond

$27.03

-0.27 (-0.99%)

FDX

FedEx

$216.00

0.92 (0.43%)

ADBE

Adobe

$156.60

0.83 (0.53%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 19

    Sep

  • 19

    Sep

  • 19

    Sep

  • 21

    Sep

  • 25

    Sep

  • 25

    Sep

  • 22

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.